{"id":"W2789468111","doi":"10.1007/s11523-018-0559-0","title":"Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis","year":2018,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Ipsen; Canadian Centre for Applied Research in Cancer Control","keywords":"Cabozantinib; Medicine; Sunitinib; Internal medicine; Sorafenib; Oncology; Hazard ratio; Renal cell carcinoma; Meta-analysis; Bevacizumab; Temsirolimus; Progression-free survival; Subgroup analysis; Confidence interval; Overall survival; Hepatocellular carcinoma; Chemotherapy; Discovery and development of mTOR inhibitors","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0006304622,0.001030165,0.01990034,0.0007520819,0.00005067696,0.000008653652,0.0002723555,0.00028099,0.0001218391],"category_scores_gemma":[0.0001019576,0.0005274687,0.002932166,0.00213786,0.000244144,0.00004321312,0.00004319188,0.0002291624,0.00001093464],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001955843,"about_ca_system_score_gemma":0.0007891983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001970364,"about_ca_topic_score_gemma":0.0009594042,"domain_scores_codex":[0.9920517,0.002986619,0.003028026,0.0008383878,0.0005093332,0.0005858881],"domain_scores_gemma":[0.9939665,0.001882243,0.002389771,0.001267064,0.0003358678,0.0001585097],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.002168489,0.004189379,0.0009010123,0.8429807,0.1339708,0.0007869894,0.003517839,0.00005984657,1.758232e-7,0.00002424165,0.0001836984,0.01121679],"study_design_scores_gemma":[0.007827555,0.04039405,0.0001600012,0.01615049,0.902218,0.00002828465,0.0004979063,0.000004226001,0.000009032134,0.000003540688,0.03233243,0.0003745051],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00533972,0.9819739,0.000001477434,0.00002194607,0.0001021203,0.01159677,0.0005085053,0.00001053468,0.0004450076],"genre_scores_gemma":[0.01377785,0.9814775,0.0008016214,0.00003506158,0.00003433058,0.002598417,0.00116028,0.00005894893,0.00005599214],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8268302,"threshold_uncertainty_score":0.9997177,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1109176175775262,"score_gpt":0.3834524545767004,"score_spread":0.2725348369991741,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}